ATLANTA--(BUSINESS WIRE)--Nov. 28, 2005--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, and RheoGene, Inc. (Norristown, PA) have signed a semi-exclusive license to use RheoGene's RheoSwitch(R) System and related technologies within Chemicon's research product lines focused on specialty research markets, including Chemicon's growing stem cell biology portfolio of products.
